Clinical Trial Update: Ustekinumab for the Treatment of Giant Cell Arteritis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of ustekinumab for Giant Cell Arteritis was terminated, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis
• Temporal Arteritis

Drugs mentioned

• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Giant Cell Arteritis, Temporal Arteritis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-06-12